Global Research Antibodies Market, by Product Type (Primary Antibodies, Secondary Antibodies, Reagents, Consumables), by Form (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), by Source (Mouse, Rabbit, Goat, Others (Guinea Pigs, Rat, etc.)), by Application (Western Blotting, ELISA, Flow Cytometry, Immunocytochemistry (ICC)/ Immunofluorescence (IF), Immunohistochemistry (IHC), Others), by End User (Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa), is estimated to be valued at US$ 3,574.6 million in 2022, and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).
Increasing number of collaborations by market players is expected to drive growth of the global research antibodies market over the forecast period. For instance, in February 2022, Abcam plc, a producer, distributor and seller of protein research tools announced collaboration with Twist Bioscience, a public biotechnology company to enhance antibody discovery for diagnostic and research applications.
Moreover, rising number of product approvals by the U.S. Food & Drug Administration are expected to propel growth of the global research antibodies market during the forecast period. For instance, in August 2020, Novartis, a global healthcare company announced its product Kesimpta (ofatumumab) received the U.S. Food & Drug Administration approval for the treatment of relapsing multiple sclerosis. Ofatumumab is monoclonal antibody and is the first and only self-administered drug to treat relapsing multiple sclerosis.
Global Research Antibodies Market - Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic has affected several markets across the globe. The COVID-19 pandemic has affected demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. However, Coronavirus (COVID-19) pandemic is expected to positively impact growth of the global research antibodies market during the forecast period Moreover, in December 2021, AstraZeneca, a multinational healthcare company, announced that Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, had received emergency use authorization (EUA) from the U.S. FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in the U.S.
Browse 53 Market Data Tables and 44 Figures spread through 249 Pages and in-depth TOC on Global Research Antibodies Market, by Product Type (Primary Antibodies, Secondary Antibodies, Reagents, Consumables), by Form (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), by Source (Mouse, Rabbit, Goat, Others), by Application (Western Blotting, ELISA, Flow Cytometry, Immunocytochemistry (ICC)/ Immunofluorescence (IF), Immunohistochemistry (IHC), Others), by End User (Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa)
To know the latest trends and insights prevalent in the Global Research Antibodies Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/research-antibodies-market-5247
Key Takeaways of the Global Research Antibodies Market:
- Global research antibodies market is expected to exhibit a CAGR of 5.9% over the forecast period (2022-2030). North America is expected to account for major market share over the forecast period (2022-2030), owing to increasing prevalence of cancer as monoclonal antibodies are used to treat various cancer such as anal cancer, bladder cancer, cervical cancer, etc. For instance, according to American Cancer Society, a nationwide voluntary health organization dedicated to eliminating cancer, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S.
- Some of the major players operating in the global research antibodies market include Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals and Abcam plc.
